Novel Immunotherapy for Hepatocellular Carcinoma06382Novel mAb targets MAN2A1-FER–positive cancers (HCC, prostate, glioblastoma), slowing growth and metastasis via PDGFRA extracellular domain binding.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasOncologyTherapeutic IndicationsHepatocellular carcinoma (HCC)TagsAntibody - mAbDrug Discovery - TargetImmunologyLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsMuhamuda KaderJianhua LuoYanping YuTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-04-21CollectionsWomen's & Reproductive Health
Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients05947Integrated transcriptome-exome sequencing with ML (Random Forest, k-top scoring pairs) to predict HCC recurrence post-liver transplant. 126 charsTechnology TypeDigital HealthTechnology SubtypeClinical Decision SupportTherapeutic AreasOncologyTherapeutic IndicationsHepatocellular carcinoma (HCC)TagsMachine learningPersonalized MedicineLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2022-01-27
Fusion Gene-Based Machine Learning Tool Enhances Prediction of Prostate Cancer Clinical Outcomes06089Fusion-gene based machine learning boosts prostate cancer recurrence predictions using 14 gene signatures across multiple cohorts.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasUrologyOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsGeneticsLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2022-07-01
Advanced Methods for Diagnosing Prostate Cancer and Predicting Relapse02406CNV-based genome analysis predicts prostate cancer progression and relapse, enabling personalized diagnostics and targeted treatment planning.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsPrecision medicineClinical Decision SupportLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsJianhua LuoGeorge MichalopoulosJoel B. NelsonTechnology Readiness Level5. Analytical validationDate Submitted2011-02-15
Targeting Chromosomal Rearrangements for Cancer Treatment03641Targeting fusion gene-driven cancers with genome-editing therapies for precise, breakpoint-specific treatment and improved outcomes.Technology TypeDiagnostic/AssayTechnology SubtypeBiomarkerTherapeutic AreasOncologyTherapeutic IndicationsHodgkin LymphomaChronic Myeloid Leukemia (CML)Chronic Lymphocytic Leukemia (CLL)Lead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsZhanghui ChenJianhua LuoGeorge MichalopoulosDate Submitted2015-06-09CollectionsWomen's & Reproductive Health
Predicting Cancer Recurrence after Liver Transplant05628A genome-based machine-learning model predicts post-transplant HCC recurrence with over 80% accuracy to guide liver transplant decisions.Technology TypeDiagnostic/AssayTechnology SubtypeBiomarkerTherapeutic AreasOncologyTherapeutic IndicationsHepatocellular carcinoma (HCC)Lead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2021-03-06
Novel Targeted Gene Therapy for Cancers06452Targeted HSV1-tk genome editing at cancer fusion breakpoints to induce tumor cell death, offering genotype-specific therapy potential.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - CRISPRTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaHepatocellular carcinoma (HCC)Lead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsMuhamuda KaderShuchang LiuJianhua LuoTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-07-06CollectionsCell & Gene Therapy
Innovative Leukocyte Genomic CNV Analysis for Predicting Prostate Cancer Outcomes03651Leukocyte CNV profiling predicts prostate cancer outcomes; improves recurrence risk accuracy when combined with Gleason, Nomogram, and fusion status.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2015-06-16
Taqman qRT-PCR Test for Fusion Genes04811TaqMan qRT-PCR detects eight fusion genes, including degraded samples, with in vivo-validated, highly sensitive diagnostics.Technology TypeLife Science Research ToolLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsJianhua LuoYanping YuDate Submitted2018-11-13
